March  2018:

MassBio Lunch and Learn

IVAL Contract Research Service: In vitro screening for human-specific adverse drug properties

Speaker: Albert P. Li, PhD, President and CEO of IVAL

Clinical trial failure is a major challenge for drug development. Reasons for the failures are unexpected adverse drug properties that, due to species difference, are not detected in nonclinical testing in laboratory animals. In the past decade, IVAL has developed highly accurate and rapid screening assays for human-specific adverse drug properties using high quality primary human hepatocytes and enterocytes. The assays require minimum test materials

Date: Tuesday March 27th

Time: 12:00 PM - 13:00 PM

Location: MassBio, Collaboration Room
300 Technology Square, 8th Floor, Cambridge MA 02139

The symposium is free to all attendees. Enjoy FREE lunch while learning about IVAL's service offerings. Register today and save your seat!


March  2018:

Please visit IVAL at the 57th Annual Meeting of the Society of Toxicology, March 11–15, 2018 in San Antonio, Texas.

Poster Session: Late-Breaking 2: Toxicokinetics

Date and Time: Thursday, March 15, 2018; 8:30 AM to 11:30 AM

Location: Convention Center Hall 1

Poster Board number: P147

Poster Title: A Novel Human Hepatocyte Exogenous Metabolic Activating System For The Evaluation Of Protoxicants

Presenting Author: Albert Li

December  2017:

Hepatocyte and Enterocyte Research Organization (HERO) Workshop and Symposium
Date: December 4th and 5th, 2017
Location: IVAL Boston Hepatocyte Technology Center, Malden, MA

Full Program of Workshop and Symposium

Li HERO Workshop Hepatocyte and Enterocyte Technologies for Drug Development

Hepatocyte and Enterocyte Laboratory Introduction

November  2017:

IVAL’s MetMax™ Technology Wins EPA’s Transform Tox Challenge

IVAL’s MetMax™ system has been selected as one of the five winners in the Transform Toxicity Challenge by National Toxicology Program (NTP) and the United States Environmental Protection Agency (EPA).

High-throughput screening (HTS) assays are deployed to rapidly test whether some of the thousands of chemicals in use may affect human health. However, current HTS assays do not fully incorporate chemical metabolism, often neglecting compounds that are metabolized to more toxic forms. The Transform Toxicity Testing Challenge was launched by EPA in January 2016 to seek novel technologies that can capture the key toxin metabolizing information.

In November 2017, IVAL’s MetMax™ technology was chosen as one of the five winners by producing “Practical designs that bring us one step closer to turning existing, commonly used in vitro high-throughput chemical screening assays into tests which evaluate both parent chemical and metabolite effects in the assay responses".

MetMax™ Human Hepatocytes (MMHH; patent pending), was developed as a convenient experimental reagent to provide hepatic metabolism to in vitro toxicity assays, including cytotoxicity and genotoxicity.

MMHH are cryopreserved permeabilized human hepatocytes supplemented with phase I and II drug metabolizing enzyme cofactors. MMHH has metabolic activities similar to conventional cryopreserved human hepatocytes, but with the conveniences of cell-free fractions such as -80 degree storage and direct thaw-and-use protocol. After thawing, MMHH can be directly added to the wells of the target cells as an exogenous metabolic system, allowing scientists to evaluate toxicants whose toxic potential was impacted by metabolism. MMHH were compatible with all high throughput screening multi-well systems, including 24, 48, 96, 384, and 1536 well plates. The permeabilized membranes of MMHH allowed ready interaction of hepatic drug metabolizing enzymes with the test compounds as well as ready diffusion of the resulting hepatic metabolites from the hepatocytes to interact with the target cells.

Proof-of-concept studies were performed on HEK 293 cells, a cell type that is not competent in xenobiotic metabolism with model pro-toxicants. Study showed that the cytotoxicity of model compounds in HEK 293 cells was significantly enhanced by the presence of MMHH, and that the metabolic enhancement could be abolished by heat-inactivation of MMHH.

MetMax™ Human Hepatocytes represent a promising experimental system to provide exogenous hepatic metabolism to in vitro toxicity assays that do not possess metabolic capacity.

For more information on IVAL's MetMax™ Hepatocyte and Enterocyte products, please go to: MetMax™ Products

Contact Veronica Huang ( to ask a question, provide feedback, or report a problem.

September  2017:

  • IVAL webinar: MetMax™ Hepatocytes and Enterocytes (Patent Pending)

View the recorded webinar video here

  • Check out the electronic version of IVAL’s posters at the 21st North American ISSX Meeting; September 24 - 28, 2017, Rhode Island Convention Center Providence, Rhode, USA

pdf icon

(1) MetMax™ Pooled Donor Human Hepatocytes: A Novel In Vitro System for the Evaluation of Hepatic Drug Metabolism Poster

pdf icon

(2) Application of MetMax™ Pooled Donor Human Hepatocytes in a High Throughput Assay for Human Hepatic Metabolic Stability Screening Poster

pdf icon

(3) Evaluation of Herb-Drug Interactions with MetMax™ Pooled Donor Human Enterocytes: Results with Twenty-Eight Commonly Used Herbal Supplements Poster

pdf icon

(4) A Comparison of Adult and Neonatal Human Hepatocytes in Drug Metabolizing Enzyme Activities Poster

March  2017:

KMT Hepatech and In Vitro ADMET Laboratories to Offer Human Hepatocytes from Chimeric Mouse

Visit IVAL in our own hometown Baltimore, Maryland at SOT (March 12 - 16, 2017), and learn more about two new IVAL products to add to your drug metabolism tool box:

**MetMax™ Cryopreserved Hepatocytes and MetMax™ Cryopreserved Enterocytes for drug metabolism, drug-drug interactions, and as exogenous metabolic activation systems for promutagens and protoxicants (Hear more about this at our Exhibitor-hosted session on Tuesday--more details below!)

Stop by booth #2439

Exhibitor-Hosted Session

**"Evaluation of Adverse Drug Properties with Cryopreserved Human Enterocytes and Hepatocytes"**

Dr. Albert P. Li, CEO and President, IVAL

The liver and intestines are two major organs with extensive xenobiotic drug metabolism activities. The application of cryopreserved hepatocytes and enterocytes to evaluate drug metabolism, drug-drug and food-drug interactions, and drug toxicity will be described. A novel system, MetMax™ hepatocytes, as an exogenous metabolic activation system for proto-toxicants, will be introduced.

Date: Tuesday, March 14, 2017
Time: 10:30 AM-11:30 AM
Room Assignment: 338
Event ID: 7

IVAL Poster Activities:

** Session Title: Food Safety and Nutrition** Wednesday, March 16, 2017 Morning session
Presenting Author: Albert Li
CC Exhibit Hall or Hall A

**Evaluation Of Herb-Drug Interactions with Cryopreserved Human Enterocytes** Abstract Number/Poster Board number: 2579/P424
Wednesday, March 15, 2017 Morning session

** Session Title: In Vitro and In Silico Approaches** Monday, March 13, 2017 Morning session
Presenting Author: Albert Li
CC Exhibit Hall or Hall A

**A Novel High-Throughput Human Hepatocyte Screening Assay for Reactive Metabolites** Abstract Number/Poster Board number: 1275/P435
Monday, March 13, 2017 Morning session

May  2016:

IVAL is named as a semi-finalist in the "Transform Tox Testing Challenge" created to improve chemical screening.

IVAL continues its series of innovative approaches to the comprehensive understanding of toxicity. The Transform Tox Testing Challenge was created by a coalition of Federal Agencies: the Environmental Protection Agency (EPA) and the National Institutes of Health (NIH) the National Center for Advancing Translational Sciences (NCTAS), National Institutes of Health NIH's Nation Toxicology Program (NPA) within the National Institute of Environmental Health Sciences (NIEHS). The purpose of the challenge is to more fully evaluate the potential harmful effects of chemicals found in the environment by using High Throughput Screening (HTS) approaches.

IVAL has developed a unique patent-pending approach using the Exogenous Metabolism System (EXM). The EXM consists of a transwell insert containing human or animal hepatocytes. The EXM insert is placed into a cell culture well containing the target cells used for toxicity evaluation, serving as an exogenous hepatic metabolic system.

For more information on the Tox Testing Challenge, Please visit


April  2016:

2016 IVAL Annual Workshop and Conference: Novel In Vitro ADMET Technologies for Drug Development

April 11th – 12th 2016 IVAL Annual Workshop: Hands-on workshop for in vitro test systems: Hepatocytes, enterocytes, and hepatocyte spheroids

April 12th 2016 IVAL Annual Conference: Novel In Vitro ADMET Technologies for Drug Development
IVAL Boston Hepatocyte Technology Center
389 Main Street, Suite 301 – 304, Malden MA, 02148 Tel: (781) 397-9300

Workshop participants will receive hands-on training in human and animal hepatocyte handling techniques in both 2D and 3D culture models. For the first time, attendees will also use enterocytes and discover how to apply enteric metabolism as an experimental system.

Our conference is intended for scientists and professionals who are interested in an updated overview about the latest drug development techniques to improve accuracy and efficiency in predicting clinical outcome from preclinical assessments using a variety of in vitro tools. Our program offers compelling presentations from our experts and industry leaders.

Registration | Program Details

March  2016:

SOT’s 55th Annual Tox Expo
March 14 – 16, 2016
New Orleans, LA

Booth #804


“Human Enterocytes: Isolation, Cryopreservation, Characterization, And Application In The Evaluation Of Drug-food Interactions”

    - Abstract Number 3146 / Poster Board number P406
    - 3/16/2016 1:15 to 4:30 PM, CC Exhibit Hall

“Prolonged Culturing Of Human Hepatocytes In Human Plasma For P450 Induction And In Vitro Hepatotoxicity Studies”

    - Abstract Number 3145 / Poster Board number P405
    - 3/16/2016 1:15 to 4:30 PM, CC Exhibit Hall

"Human Hepatocyte/Kupffer Cell 3D Spheroid Co-Cultures: Characterization and Application for DILI Studies"

    - Abstract Number 1995 / Poster Board number P347
    - 3/15/2016 9:30 AM to 12:45 PM, CC Exhibit Hall

Exhibitor Hosted Session:

Monday, March 14, 2016
Time: 3:00 - 4:00 PM
Room: 205

“Cryopreserved Human Enterocytes and Hepatocytes for the Evaluation of Adverse Drug Properties”

Orally administered xenobiotics are subjected in intestinal metabolism/absorption and hepatic metabolism/systemic circulation. The isolation and characterization of human and animal enterocytes, and the application of enterocytes in conjunction with hepatocytes to define adverse drug properties including metabolism, drug-drug interactions, and toxicity will be described.

Dr. Li will also serve as session chair for the following poster session:

Tuesday, March 15 9:30 AM - 12:45 PM
CC Exhibit Hall

News Archive

February 2016:

IVAL Webinar: Hep-I-Spheres: 3D in vitro liver test systems for ADME-Tox research
February 24, 2016

Hep-I-Spheres, IVAL's newly-developed hepatocyte spheroids, are a useful tool for preclinical toxicity assessment of new compounds. These uniform and organized cell aggregates offer liver-like morphology and function in long-term cultures that can closely simulate in vivo drug exposure conditions.

This webinar will discuss our development of reproducible primary human hepatocyte spheroids, discuss data from both mono-culture and co-culture preparations, and help attendees better understand how studies performed using this test system bring additional value to their drug development program.

    January 2016:

    Delaware Valley Drug Metabolism Discussion Group (DV DMDG) Vendor Show
    January 28, 2016
    Langhorne, PA

    Presentation by Dr. Albert P. Li:

    "Cryopreserved enterocytes for the evaluation of metabolic fate and drug-drug interactions of orally administered drugs."

    December 2015:

    Webinar: "Enterocytes and their importance in preclinical pharmaceutical development efforts"
    December 3rd, 2015
    11:00 am Eastern / 8:00 am Pacific

    Enterocytes are responsible for first-pass metabolism and are the key cell type for assessing oral bioavailability. With CYP3A4 activity comparable to that of human hepatocytes, enterocytes are a useful in vitro test system for the investigation of intestinal drug metabolism, drug-drug interactions, and toxicity assessments.

    In this webinar, you will learn how IVAL's cryopreserved enterocytes maintain their enzyme activity after thawing and have been shown to produce clinically-observed phenomena, such as time-dependent inhibition of CYP3A4 by grapefruit juice.

    Download the Poster |Watch the Webinar Recording

    November 2015:

    30th JSSX Annual Meeting
    November 12 - 14, 2015
    Tokyo, Japan

    Luncheon Seminar 9:
    Saturday, November 14, 2015
    Time: 12:30 - 1:30 PM
    Room D (2F Heian)

    Dr. Albert Li will present “Novel Human Hepatocyte Technologies for Drug Development” Human hepatocytes represent the gold standard for the evaluation of human drug metabolism, drug-drug interactions, and hepatotoxicity. The current status of this experimental tool will be reviewed, with emphasis placed on recent technical advances which include approaches to predict human hepatotoxicity and evaluation of low hepatic clearance compounds.

    October 2015:

    October 2, 2015
    Pharmaceutical & BioScience Society (PBSS) meeting
    Cambridge, MA

    IVAL will host an exhibit and attend the upcoming Pharmaceutical & BioScience Society (PBSS) meeting, titled: "Lead Identification and Candidate Nomination: Target selection, Hit to Lead Optimization, ADMET Properties and Dose Projection"

    Speakers: Raj Nagaraj (Agios), Scott Obach (Pfizer), Daf Owen (Pfizer), Chandra Prakash (CP Pharma Consulting), Sanjeev Thohan (Novartis), Cindy Xia (Takeda)

    This workshop will describe the strategies and current approaches for lead identification/optimization and selection of a drug development candidate. With a faculty of distinguished speakers who are highly regarded experts and key opinion leaders on this topic, this workshop intends to provide the strategies for:

    • Target selection, CIR, Hit to Lead Optimization
    • Metabolic stability and reactive metabolites screen
    • In vitro assessment of CYP inhibition/induction liability
    • In vitro Assessment of Permeability and transporters
    • In vivo PK, Protein binding and human dose prediction with case studies
    • In vitro/in vivo tools for toxicity

    October 18 – 22, 2015
    20th North American ISSX Meeting
    Orlando, FL

    ISSX is a great meeting to renew past acquaintances and to meet new colleagues. Visit us at Booth #306 or talk with our scientific staff at the interactive poster sessions, where discussion about our latest research can bring fresh insights.


    • "Long-term culturing of human hepatocytes in human plasma"
    • "Isolation and cryopreservation of enterocytes for metabolism and uptake studies
    • "A 384-well plate high throughput assay for the evaluation of time-dependent inhibition of CYP3A4 in human hepatocytes"
    • Reaction phenotyping of slowly metabolized compounds using the plated hepatocyte relay method in combination with mechanism-based isoform-specific P450 inhibitors

    This meeting brings 1,000 or more industry professionals together to share ideas about the latest advances in drug development.

    September 2015:

    Sept 10, 2015
    Delaware Valley Drug Metabolism Discussion Group (DV DMDG) Biomarker Symposium
    Langhorne, PA

    Sept 16, 2015
    New England Drug Metabolism discussion Group (NE DMDG) Fall Meeting
    Speaker: A. David Rodrigues: "Endogenous Probes for Drug-Metabolizing Enzymes and Transporters: Where are we now?"
    Boston, MA

    Sept 20 – 23
    Linz 2015 19th European Congress on Alternatives to Animal Testing
    Dr. Albert Li will discuss "Cryopreserved human hepatocytes and IdMOC experimental system for the evaluation of human drug properties"
    Linz, Austria

    September 21 – 24, 2015
    18th Annual LOL Conference on Drug Metabolism / Applied Pharmacokinetics
    Madison, WI

    IVAL is sponsoring the open reception to kick off this 3-day focused program titled: "Factors Influencing the Future of Drug Metabolism and Pharmacokinetics"

    This is an educational forum to discuss current issues in selecting potential new candidates for drug development. Topics include drug metabolism, drug transport, and PK/PD.

    July 2015:

    July 23, 2015
    Boston Society HT-ADME
    Cambridge, MA

    IVAL is a proud sponsor of this one-day meeting titled: "Technology and applications of ADME in early drug discovery."

    Keynote Speaker - Charlotte Allerton, Pfizer, VP, Head of Pharmacokinetics, Dynamics and Metabolism NCE, "Evolution of DMPK Impact on Drug Design"

    Keynote Speaker - Litao Zhang, PhD., Vice President Leads Discovery and Optimization, Bristol-Myers Squibb, "The Changing Face of Science and Technology Innovation in Drug Discovery: Accelerating the Identification of High Quality Drug Candidates through Parallel SAR and SLR Screening"

    June 2015:

    IVAL will have representatives at the 18th International Conference on Drug-Drug Interactions in Seattle, WA, June 29th – July 1st

    June 13, SAPA-NE, MIT Tang Center, Cambridge, MA. IVAL was a gold sponsor of the program and Dr. Albert Li presented "Novel human hepatocyte tools for drug development"

    June 11th, IVAL was a sponsor at the NE DMDG meeting in Burlington, MA

    June 10th, IVAL hosted the June Speaker Series event for members and guests of The Business Coalition (TBC) from 6:00 to 8:00 pm at our Boston Hepatocyte Technology Center, 389 Main Street, Suite 301 – 304, Malden, MA 02148. Dr. Albert Li, President and CEO of IVAL joined Mayor Gary Christenson, City of Malden, and Kevin Duffy, Malden Strategy and Business Development Officer to deliver presentations at this evening program and mixer. Check-in begins at 5:30 pm. Click here to register.

    May 2015:

    IVAL is a Bronze Sponsor of the GL DMDG meeting in Ann Arbor, MI, May 7th – 8th

    April 2015:

    IVAL-BHTC Hepatocyte Workshop
    April 13th and 14th

    Location: IVAL-Boston Hepatocyte Technology Center
    389 Main St, Malden, MA

    Join other scientific professionals learning how to optimize hepatocyte cultures for drug development applications and get the most reliable data from scientific investigations. Our workshops include lectures, practical hands-on training and an open classroom discussion. You'll take away some tips and tricks that you can start using right away. Workshop attendance is limited—register soon to reserve your spot. For additional details and registration information, please download the flyer or email us at

    IVAL Hepatocyte Technology Conference 2015:
    Prediction of Human Drug Properties
    April 14th

    Location: IVAL-Boston Hepatocyte Technology Center
    389 Main St, Malden, MA

    A major challenge in drug development is clinical trial failure due to inaccurate preclinical assessment of human drug properties. In this conference, our internationally-renowned faculty will dissect the key factors contributing to the high cost of drug development, and discuss promising approaches to enhance the efficiency of drug development via accurate assessment of human ADMET drug properties.

    • Joseph A. DiMasi, Tufts Center for the Study of Drug Development
      "The Cost to Develop and Win Marketing Approval for a New Drug"
    • Albert P. Li, In Vitro ADMET Laboratories
      "Accurate assessment of human ADMET drug properties with human hepatocytes: Challenges and accomplishments"
    • R. Scott Obach, Pfizer
      "Understanding of Hepatic Drug Metabolism Using Human Hepatocytes"
    • A. David Rodrigues, Pfizer
      "In Vitro Phenotyping of Liver Uptake Transporters; A Report from the Front Line"
    • Yuichi Sugiyama, RIKEN Research Cluster for Innovation
      "The Use of "Extended Clearance Concept" and PBPK Modeling to Interpret Clinical Outcomes from In Vitro Metabolism and Transport Data"
    • Sandy Pang, University of Toronto
      "Chimeric Mouse Liver Models"

    Early bird registration through March 31st. To download a printable flyer and registration form, click here. Contact us at with any questions.

    March 2015:

    ENDO 2015
    March 5th and 8th

    Location: San Diego, CA

    The Novel IdMOC Experimental System for in Vitro Evaluation of Cell-Cell Interactions
    Speaker: Albert P. Li, In Vitro ADMET Laboratories LLC, Columbia, MD

    Date: Friday, March 6, 2015

    Time: 1:00 – 3:00 PM

    Room: Expo Hall, San Diego Convention Center

    Poster Board Number: FRI-336

    The novel integrated discrete multiple organ co-culture (IdMOC) experimental system allows the co-culturing of multiple cell types as physically separated entities but interconnected by a common overlying medium. The system employs a wells-in-a well concept, with multiple shallow wells inside a larger containing well. The formats include 6, 48, and 96 inner wells within each containing well. As the IdMOC plates have the same foot-print of regular 24- and 96-well plates, experiments can be performed with the plates without the need of special equipment as required for micro-fluidic co-culture systems. The IdMOC system can be used with adherent cells as well as non-adherent cells as matrigel entrapped cultures. Proof of concept experiments were performed demonstrating endocrinal cell-cell interactions, with soluble factors produced by one cell type interacting with a different cell type in the co-culture. Primary human hepatocytes and primary human splenocytes were plated in IdMOC-96 plates (96-well plate format, with 16 containing wells each with 6 inner wells). The co-cultures were treated with cyclophosphamide at 100, 200, 500, 1000 and 2000 uM. In vitro immunotoxicity was quantified via ATP contents in the presence and absence of phytoagglutinant A (PHA), with PHA-induced cell proliferation as a measurement of immune function. Cyclophosphamide induction of immunotoxicity was observed in splenocytes co-cultured with hepatocytes, but not in the absence of hepatocyte co-culture. The results suggest that IdMOC system can be used for in vitro evaluation of cell-cell interactions via secreted soluble factors. Examples of applications include the evaluation of endocrinal interactions among cells of different organs, and paracrinal interactions among cells from the same organ. For more information, visit the ENDO 2015 website.

    Society of Toxicology Annual Meeting
    March 22nd and 26th

    Location: San Diego, CA

    IVAL Booth 1420
    Our Posters:

    Elucidation of the Roles of P450 CYP3A and Uptake Transporters in Species Differences in Drug Toxicity Using Cryopreserved Knockout and Humanized Transgenic Mouse Hepatocytes

    • Presenting Author: Albert Li
    • Session Title: Biotransformation and Cytochrome P450
    • Abstract Number 89 / Poster Board Number 122
    • Monday, March 23rd, 9:30 AM to 12:30 PM

    Plateable Cryopreserved Human Hepatocytes Pooled from Multiple Donors for In Vitro Evaluation of Adverse Drug Properties

    • Presenting Author: Utkarsh Doshi
    • Session Title: Liver and Models
    • Abstract Number 695 / Poster Board Number 549
    • Monday, March 23rd, 1:00 PM to 4:30 PM
    Exhibitor Hosted Session:

    In vitro hepatotoxicity evaluation with cryopreserved human, animal and transgenic animal hepatocytes

    • Presenting Author: Dr. Albert Li
    • Tuesday, March 24th, 10:00 – 11:00 am
    • Room 24C

    November 2014:

    IVAL-BHTC Hepatocyte Workshop
    Nov 17th (full day) and 18th (half day)

    Join other scientific professionals learning how to optimize hepatocyte cultures for drug development applications and get the most reliable data from scientific investigations. Our workshops include lectures, practical hands-on training and an open classroom discussion. You'll take away some tips and tricks that you can start using right away. Workshop attendance is limited—register soon to reserve your spot. For additional details and registration information, please click here.

    October 2014:


    IVAL exhibited and presented three scientific posters on recent hepatocyte-based research at the 2014 ISSX / JSSX Joint Meeting, San Francisco, CA this October 29th – 23rd.

    Our posters:

    1. Plated Hepatocyte Relay Assay (PHRA) for the estimation of intrinsic hepatic clearance and metabolite profile of slowly metabolized compounds

      Poster P28, Session 1: Monday, October 20, 12:30 – 2:00 pm

    2. Development of a relay assay with plated human hepatocytes for the evaluation of slowly metabolized compounds

      Poster P29, Session 1: Monday, October 20, 12:30 – 2:00 pm

      Selected for oral presentation:
      Tuesday Oct 21, 5:15 – 5:30 pm, Imperial Ballroom
      Symposium 8: Solving ADME/Tox Challenges in Drug Discovery

    3. Multiple donor pooled plateable cryopreserved human hepatocytes for P450 induction studies

      Poster P240, Session 3: Tuesday, October 21, 12:30 – 2:00 pm


    IVAL was a proud sponsor of the 10th annual meeting of the Hepatocyte Research Association: which was a satellite meeting at the ISSX, Wednesday, October 22nd.

    Advances and Application of Functional Hepatocytes Symposium:

    Dr. Albert P. Li, CEO and owner of In Vitro ADMET Laboratories, participated in the Advances and Application of Functional Hepatocytes Symposium, held Oct. 29 - 30, 2014 at the Shanghai Institute of Biochemistry and Cell Biology, Shanghai, China.

    Experts from around the world delivered presentations on generating and using functional hepatocytes in industrial and therapeutic applications. Future technologies were also presented, such as stem cell research, hepatocyte transplant therapies and liver tissue engineering breakthroughs.

    Dr. Li was on the organizing committee, and chaired the session on Industrial Applications of Functional Hepatocytes, which covered topics including drug transporters, drug metabolism, evaluating adverse drug properties, and humanized mice applications.

    Symposium Organizing Committee:

    • Lijian Hui (Shanghai Institute of Biochemistry and Cell Biology, CAS, China)
    • Guoyu Pan (Shanghai Institute of Materia Medica, CAS, China)
    • Stephen Strom (Karolinska Institutet, Sweden)
    • Albert P. Li (In Vitro ADMET Laboratories, LLC, USA)

    Click here for the program.